Production of recombinant adeno-associated virus 5 using a novel self-attenuating adenovirus production platform.

ABSTRACT: Recombinant adeno-associated virus (rAAV) has become a prominent vector for clinical use. Despite an increase in successful clinical outcomes, the amount of high-quality rAAVs required for clinical trials and eventual commercial demand is difficult to produce, especially for genetic diseases that are prevalent or require high doses. Many groups are focused on establishing production processes that can produce sufficient rAAV while maintaining potency and quality. Our group used a novel production platform to increase our yield of rAAV5. This production platform uses tetracycline-enabled self-silencing adenovirus (TESSA) to deliver the wild-type AAV replication and capsid genes alongside the adenovirus helper genes necessary for production. Here, we describe our efforts to evaluate the TESS

SUBMITTER: Roach MK 

PROVIDER: S-EPMC11399549 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature